Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mix of positive and negative elements. Financial performance shows a decrease in net loss and R&D expenses, but the need for additional funding is a concern. Product development and market potential are promising, but competition and regulatory risks persist. The Q&A section revealed some uncertainties, particularly around AI platform commercialization and funding. Positive aspects like geographic expansion and AI advancements are balanced by risks and funding needs, leading to a neutral sentiment. Without market cap information, the impact on stock price remains uncertain, suggesting a neutral prediction.
Key Financial Performance
General and Administrative Expenses Approximately $1.51 million for Q1 2025, up from approximately $1.48 million in Q1 2024.
R&D Expenses Approximately $3.3 million for Q1 2025, down from approximately $4.3 million in Q1 2024. The decrease was primarily due to reductions in CRO and clinical site costs for LP-184.
Net Loss Approximately $4.5 million for Q1 2025 or $0.42 per share, compared to a net loss of approximately $5.4 million or $0.51 per share for Q1 2024.
Cash Position Approximately $19.7 million as of March 31, 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
LP-184 Clinical Progress: Phase 1a trial for LP-184 has progressed well with enrollment through cohort 12, expecting to complete enrollment with 62 to 65 patients by June 2025.
LP-184 Fast Track Designations: LP-184 holds dual fast track designations for glioblastoma and triple-negative breast cancer, plus four rare pediatric disease designations.
LP-300 HARMONIC Trial: Strong progress in HARMONIC Phase 2 trial for LP-300 with enrollment in Japan and Taiwan, showing an 86% clinical benefit rate.
STAR-001 Development: Advancing STAR-001 for CNS and brain cancers, with a Phase 1b/2 trial in recurrent GBM anticipated to begin in late 2025.
Market Potential for LP-184: Estimated annual market potential for LP-184’s target indications is about $14 billion, with $4 billion to $5 billion for CNS cancers and $10 billion for other solid tumors.
Market Opportunity in TNBC: The market potential for metastatic TNBC is estimated to exceed $4 billion annually.
Market Opportunity in Lung Cancer: The market opportunity for drug-resistant non-small cell lung cancer is estimated to exceed $2 billion annually.
Cash Position: Ending the quarter with approximately $19.7 million in cash, providing an expected operating runway through at least mid-May 2026.
Net Loss Reduction: Quarterly net loss decreased to approximately $4.5 million compared to $5.4 million in the same period last year.
AI Platform Expansion: Radar AI platform grew to approximately 200 billion oncology focused data points, with plans to open it to the broader scientific community.
Agentic AI Capabilities: Plans to integrate agentic AI capabilities into the radar platform, transforming it into a true development partner for drug discovery.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company cautions that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated.
Clinical trial results: Results of clinical trials could significantly impact the company's future performance and market position.
Competition: The impact of competition in the oncology market could affect the company's ability to capture market share and achieve projected revenues.
Regulatory approvals: The company is dependent on regulatory approvals for its clinical trials, which could pose a risk if not granted.
Funding needs: The company will need additional funding in the near future to support its operations and clinical trials.
Market potential: The estimated market potential for LP-184 and other products is significant, but actual market capture is uncertain due to various competitive and regulatory factors.
Operational efficiency: The company aims to maintain operational efficiency, but any setbacks in clinical trials or operational execution could impact financial performance.
AI platform commercialization: The success of the AI platform's commercialization is uncertain and could affect future revenue streams.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Clinical Pipeline Progress: Advancements in clinical programs, particularly LP-184, with enrollment expected to complete by June 2025. Early indications of clinical activity observed.
AI Platform Advancements: Expansion of the radar AI platform to over 200 billion oncology-focused data points, with plans to commercialize modules to the scientific community.
Shareholder Value Maximization Initiatives: Disciplined capital management with $19.7 million in cash, focusing on operational efficiency and potential partnerships.
Partnership Discussions: Entering discussions with biopharma partners for licensing agreements and co-development.
Revenue Expectations: Potential market opportunities exceeding $4 billion annually for metastatic TNBC and $2 billion for drug-resistant non-small cell lung cancer.
Financial Projections: Expected operating runway through mid-May 2026 with a net loss of approximately $4.5 million for Q1 2025.
Future Trials: Initiation of FDA cleared Phase 1b/2 trials for LP-184 in TNBC and non-small cell lung cancer.
Market Potential: Estimated annual market potential for LP-184’s target indications is about $14 billion.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash Position: Approximately $19.7 million in cash, cash equivalents, and marketable securities as of March 31, 2025.
Net Loss: Net loss of approximately $4.5 million for Q1 2025, down from $5.4 million in Q1 2024.
Shares Outstanding: 10,784,725 shares of common stock outstanding, with a total fully diluted shares outstanding of approximately 12.1 million.
Funding Needs: The company will need additional funding in the near future.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the broader plans to roll out AI modules, and will there be a fee for access?
A:We're going to start with a freemium type approach to get people used to getting questions answered using this method. We aim to drive collaboration and monitor the type of data and use that the research community has.
Q:Are you aggregating additional data to strengthen the platform?
A:Yes, we will aggregate additional data as more people start using these modules.
Q:Is the Asian cohort still enrolling more patients in the U.S. for the HARMONIC trial?
A:The lead in cohort was seven patients in the U.S., and we had a good heterogeneous population. The expansion cohort will include both U.S. and Asian patients, but it's randomized.
Q:What is the status of the LP-184 trial?
A:We expect the trial to be fully enrolled next month, with preliminary data available shortly after that.
Q:Will the FDA use AI in its evaluation of scientific literature and data?
A:Yes, I believe the FDA will use AI in its evaluations, which will help reduce costs and speed up processes.
Q:What are your thoughts on new funds in AI?
A:AI funds are aggressively looking at AI, which will help our long-term profile and attract new investors.
Q:Review of Unclear Management Responses
A:Management did not provide a direct answer regarding the specific timeline for the rollout of AI modules or the details of the business models underlying the introduction of these modules.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI module
CFO Margrave
PCT
Phase study
Sharma President
ability
accuracy
advancement
advantage
algorithm
antibody drug
barrier
bladder cancer
combination strategy
compound
conjugate development
development module
drug conjugate
expansion cohort
funding
inflection point
objective
oncology point
pathway
payload
period
pillar
platform oncology
prediction
process
radar AI
remark
research community
selectivity
shareholder value
subsidiary Starlight
technology
track designation
LTRN Transcript
Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript
Unknown3-30
The earnings call presents a mixed picture. While the company is making progress in product development and AI expansion, it faces significant risks, including funding challenges and competitive pressures. Financial metrics show reduced losses, but the need for additional funding and operational risks dampen enthusiasm. The absence of shareholder return discussions and unclear management responses in the Q&A further contribute to a neutral sentiment.
Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call indicates a positive sentiment due to the commercialization of the RADR AI platform with high predictive success, optimistic financial guidance, and strategic advancements like the withZeta AI system. Despite challenges in market conditions and regulatory hurdles, the company shows resilience with strategic execution and competitive positioning. The Q&A session provided clarity and positive updates, particularly on trials and AI platform rollout. The decrease in R&D expenses and slight improvement in net loss also contribute to a positive outlook, warranting a 'Positive' rating for the stock price movement.
Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call Transcript
Unknown5-16
The earnings call presents a mixed picture. The company beat EPS expectations, which is positive, but lacks clarity on shareholder returns and specific strategic details. The AI platform expansion and clinical trial progress are promising, yet the market faces risks from competition and regulatory issues. The Q&A session revealed some uncertainty about AI integration timelines and FDA processes. Without a clear market cap and given the absence of strong catalysts or new partnerships, the stock is likely to remain neutral in the short term.
Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript
Unknown5-15
The earnings call presents a mix of positive and negative elements. Financial performance shows a decrease in net loss and R&D expenses, but the need for additional funding is a concern. Product development and market potential are promising, but competition and regulatory risks persist. The Q&A section revealed some uncertainties, particularly around AI platform commercialization and funding. Positive aspects like geographic expansion and AI advancements are balanced by risks and funding needs, leading to a neutral sentiment. Without market cap information, the impact on stock price remains uncertain, suggesting a neutral prediction.
LTRN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
